Eumentis Therapeutics, Inc.
EuMentis Therapeutics is a clinical stage biopharmaceutical company dedicated to developing novel therapies for serious neuropsychiatric conditions. The company integrates clinically validated science with cutting-edge technology to create effective treatments for conditions like Tourette syndrome and autism spectrum disorder, focusing on restoring balance in neurotransmitter systems.
Industries
Nr. of Employees
small (1-50)
Eumentis Therapeutics, Inc.
Boston, Massachusetts, United States, North America
Products
PDE10A inhibitor candidate for Tourette syndrome
A selective PDE10A small‑molecule candidate designed to modulate striatal dopamine circuits to reduce motor and vocal tics; advanced into clinical development with a Phase 2 trial planned.
Low‑trapping NMDA receptor antagonist candidate for autism spectrum disorder
A noncompetitive, low‑trapping NMDA receptor antagonist developed to inhibit overactive glutamate signaling in selected ASD patients identified by an imaging biomarker; undergoing Phase 2 clinical study.
NMDA antagonist program for traumatic brain injury
Development of an NMDA receptor antagonist to reduce glutamate‑mediated excitotoxicity after traumatic brain injury, aimed at accelerating recovery and reducing long‑term disability; program supported by a government research award.
PDE10A inhibitor candidate for Tourette syndrome
A selective PDE10A small‑molecule candidate designed to modulate striatal dopamine circuits to reduce motor and vocal tics; advanced into clinical development with a Phase 2 trial planned.
Low‑trapping NMDA receptor antagonist candidate for autism spectrum disorder
A noncompetitive, low‑trapping NMDA receptor antagonist developed to inhibit overactive glutamate signaling in selected ASD patients identified by an imaging biomarker; undergoing Phase 2 clinical study.
NMDA antagonist program for traumatic brain injury
Development of an NMDA receptor antagonist to reduce glutamate‑mediated excitotoxicity after traumatic brain injury, aimed at accelerating recovery and reducing long‑term disability; program supported by a government research award.
Services
Biomarker licensing for patient selection in NMDA antagonist trials
License and application of a neuroimaging biomarker to identify patients with elevated anterior cingulate glutamate for inclusion in NMDA antagonist studies.
Clinical development and trial sponsorship (Phase 1–2)
Sponsorship and execution of early‑stage clinical trials for CNS indications including planning, operational oversight and data generation for Phase 1 and Phase 2 studies.
Partnerships, licensing and investor engagement
Formation of strategic partnerships, licensing arrangements and investor outreach to advance programs and fund development.
Biomarker licensing for patient selection in NMDA antagonist trials
License and application of a neuroimaging biomarker to identify patients with elevated anterior cingulate glutamate for inclusion in NMDA antagonist studies.
Clinical development and trial sponsorship (Phase 1–2)
Sponsorship and execution of early‑stage clinical trials for CNS indications including planning, operational oversight and data generation for Phase 1 and Phase 2 studies.
Partnerships, licensing and investor engagement
Formation of strategic partnerships, licensing arrangements and investor outreach to advance programs and fund development.
Expertise Areas
- Neuropsychiatric drug development
- Pediatric neuropsychiatric indications (Tourette syndrome, autism spectrum disorder)
- Precision medicine and biomarker development
- CMC and formulation development for small molecules and biologics
Key Technologies
- NMDA receptor pharmacology (low‑trapping antagonists)
- PDE10A‑targeted small‑molecule pharmacology
- Neuroimaging biomarkers for glutamate (anterior cingulate)
- Circuit‑selective pharmacology